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Simple Summary: Currently, it is unclear which kind of axillary staging surgery breast cancer pa-
tients with lymph node metastasis should receive after neoadjuvant chemotherapy. For decades,
these patients have been treated with a full axillary lymph node dissection, even if they converted to
clinical node negativity. However, the removal of a large number of lymph nodes during the proce-
dure can increase arm morbidity and impact quality of life. Therefore, several studies investigated
less radical surgical strategies in this setting, such as sentinel lymph node biopsy or targeted axillary
dissection, i.e., removal of a previously marked node combined with sentinel node removal. In this
review, we summarize current evidence on the different surgical techniques and compare national
and international recommendations. We show that many questions regarding oncological safety
of different surgery types and the optimal marking technique remain unanswered and present the
multinational prospective cohort study AXSANA that will address these open issues.
Abstract: In the last two decades, surgical methods for axillary staging in breast cancer patients
have become less extensive, and full axillary lymph node dissection (ALND) is confined to selected
patients. In initially node-positive patients undergoing neoadjuvant chemotherapy, however, the
optimal management remains unclear. Current guidelines vary widely, endorsing different strategies.
We performed a literature review on axillary staging strategies and their place in international recom-
mendations. This overview defines knowledge gaps associated with specific procedures, summarizes
currently ongoing clinical trials that address these unsolved issues, and provides the rationale for
further research. While some guidelines have already implemented surgical de-escalation, replacing
ALND with, e.g., sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) in cN+
patients converting to clinical node negativity, others recommend ALND. Numerous techniques are
in use for tagging lymph node metastasis, but many questions regarding the marking technique, i.e.,
the optimal time for marker placement and the number of marked nodes, remain unanswered. The
optimal number of SLNs to be excised also remains a matter of debate. Data on oncological safety and
quality of life following different staging procedures are lacking. These results provide the rationale
for the multinational prospective cohort study AXSANA initiated by EUBREAST, which started
enrollment in June 2020 and aims at recruiting 3000 patients in 20 countries (NCT04373655; Funded
by AGO-B, Claudia von Schilling Foundation for Breast Cancer Research, AWOgyn, EndoMag,
Mammotome, and MeritMedical).
Keywords: neoadjuvant therapy; breast cancer; therapy response; targeted axillary dissection;
marked lymph node
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1. Introduction
In breast cancer patients, the optimal surgical management of the axilla has been
controversially discussed over the last two decades. For many years, axillary lymph node
dissection (ALND) has been considered as the standard of care. The rationale behind this
was firstly to assess the pathological lymph node status (diagnostic value, “staging”) and
secondly to provide locoregional control (therapeutic value). Due to its high morbidity, this
approach has gradually been abandoned in favor of sentinel lymph node biopsy (SLNB), a
less invasive procedure for axillary staging of clinically node-negative patients, over the
past two decades. In recent years, SLNB has also become standard of care for patients
with clinically unsuspicious nodes at time of diagnosis who have completed neoadjuvant
chemotherapy. The detection rate and accuracy of SLNB are excellent in this setting, and
axillary recurrence rates are negligible [1–3].
Nonetheless, in patients with clinically apparent axillary lymph node metastases
(cN+) at time of diagnosis who achieve complete clinical response in the axilla (ycN0) after
neoadjuvant chemotherapy (NACT), it is unclear which axillary surgical staging strategy
should be offered. This uncertainty is expressed in the heterogeneity of recommendations
endorsed by different national and international societies, which range from SLNB to
targeted axillary dissection (TAD) or ALND (Tables 1 and 2). Some societies do not
consider SLNB standard of care in this setting because of the relatively high false negative
rates (FNRs) reported in large prospective trials and confirmed in a meta-analysis [1,4–6].
In the SENTINA and the ACOSOG Z1071 trials, FNRs were 12% and 14% respectively, and
thus higher than the arbitrarily chosen but widely accepted cut-off value of 10% (Table 3).
So far, however, only limited data regarding the oncologic outcome following SLNB alone
are available in this setting [3].
Table 1. Axillary surgical staging techniques: The most important definitions.
Type of Surgery Description
Axillary lymph node dissection (ALND)
Systematic removal of lymph nodes from the
axilla, usually level I and II, sometimes
including also level III
Sentinel lymph node biopsy (SLNB)
Identification and removal of the sentinel
lymph node, usually using radioactive tracer
(Technetium-99) or blue dye
Targeted lymph node biopsy (TLNB) Selective removal of metastatic lymph node(s)marked before neoadjuvant therapy
Targeted axillary dissection (TAD) Combination of TLNB and SLNB
Marking positive lymph nodes at the time of diagnosis and prior to neoadjuvant
chemotherapy with clips, coils, radioactive seeds, or other markers may improve the FNR
of de-escalated surgical staging procedures [7,8]. The best marking technique, however,
has not been unanimously identified yet. Importantly, data comparing recurrence rates
and surgical morbidity among SLNB, ALND, and TAD are so far not available.
As a result, the German S3 guidelines updated in 2020 recommend ALND after NACT
in cN+ patients, as do Austrian and Scandinavian guidelines. As a contrast, high-impact
networks such as European Society of Medical Oncology (ESMO) in Europe and National
Comprehensive Cancer Network (NCCN) in the USA recommend SLNB, provided that
dual tracers are used and a minimum of three sentinel nodes are removed [9,10]. In
countries such as Italy, Denmark, Russia, and Hungary, SLNB or TAD are accepted as first
choice for axillary staging in this group of patients. The German Breast Committee of the
Working Group for Gynaecological Oncology (AGO Breast Committee) endorses both TAD
and ALND as recommended strategies [11].
Unanswered questions include the role of axillary imaging for selection of patients
who might safely be offered surgical de-escalation [12]. Further, the necessity of regional
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therapy, e.g., radiotherapy following axillary staging in patients with pathological complete
response on SLNB or TAD, is still a matter of debate.
Table 2. National and international guidelines on axillary surgical staging in initially node-positive patients receiving
neoadjuvant therapy.
National/International: Staging Recommendation for cN+→ ycN0 Patients Level of Evidence/Grade ofRecommendation
European Society for Medical Oncology
(ESMO) [10]
Sentinel lymph node biopsy (SLNB) can be an option, as
long as additional recommendations are followed (e.g.,
dual tracer, clipping/marking of positive nodes,
minimum of three sentinel nodes removed)
III, B
National Comprehensive Cancer Network
(NCCN) [9]
Consider SLNB. Relatively high false-negative rate (FNR)
(>10%) can be improved by marking biopsied lymph
nodes to document their removal, using dual tracer, and
by removing more than 2 sentinel nodes
2B
American Society of Breast Surgeons [13]
If SLNB after neoadjuvant therapy is attempted, dual
tracer should be used. If a SLN and/or the clipped node
(if clipped) is not identified, an Axillary lymph node
dissection (ALND) is recommended
Not provided
Finland [14] ALND Not provided
Germany (S3 guideline) [15] ALND 2b, B
Germany (AGO Breast Committee) [11]
Targeted axillary dissection (TAD): + (i.e., this
investigation or therapeutic intervention is of limited
benefit for patients and can be performed)
ALND: + (i.e., this investigation or therapeutic
intervention is of limited benefit for patients and can be
performed)
SLNB only: +/− (i.e., this investigation or therapeutic
intervention has not shown benefit for patients and may
be performed only in individual cases. According to




SLNB, preferably with double tracer technique (isotope +
dye), and with at least 3 SLNs removed; in case of limited
axillary tumor load and a realistic chance of cN1→ ycN0
conversion, clipping the metastatic node before
neoadjuvant chemotherapy (NACT) is recommended
Not provided
India [17] No specific recommendation for cN+ ycN0 patients Not provided
Poland [18]
SLNB can be an option with some limitations:
• Remove ≥ 3 SLN if nodes were not
clipped/marked; if not fulfilled,→ ALND [2+]
• Dual tracer (radiocolloid and patent blue) [2+]
• Additional option is clipping/marking lymph
nodes before NACT [0]
• Remove all clipped lymph nodes and SLNs, if not
fulfilled→ ALND [2+]
• For identification of clipped nodes intraoperative
ultrasound or guidewire is recommended [0]
• Techniques with ferromagnetic tracer [0]
Power of recommendation in square
brackets (score −2, −1, 0, 1+, 2+)
Romania
Last approved national guideline (2009) [19]: ALND is
recommended, SLNB is not recommended after NACT
New version proposed by the Romanian Society of
Obstetrics and Gynecology (2019; not approved by the
Ministry of Health) [20]: Suspicious lymph nodes must
be biopsied, and clipped if possible; if SLNB after NACT
is attempted, dual tracer is recommended
Not provided
Sweden [21] ALND Grade +++Recommendation: B
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Table 2. Cont.
National/International: Staging Recommendation for cN+→ ycN0 Patients Level of Evidence/Grade ofRecommendation
Society Guidelines
Denmark (Danish Breast Cancer Cooperative
Group) [22]
TAD including double tracer technique (radioactive
tracer plus dye)
Target lymph node(s) to be marked with radioactive
iodine seeds or coils
Not provided
Italy (Assoziacione Italiana de Oncologica
Medica = AIOM) [23]
SLNB; ALND omission may be considered in the case
one or more negative sentinel lymph nodes, identified
with double tracer and only in patients who were cN1/2
at time of diagnosis
Quality of evidence: Low
Strength of Recommendation: Weak
Portugal (Portuguese Society of Senology) [24]
cN1 patients should be clipped and ycN0 patients should
be managed by TAD, with omission of ALND in ypN0 if
the following criteria are fulfilled: (1) SLNB performed
using dual traced, (2) clipped node removed, and (3)
more than 2 removed nodes
Not provided
Russia (Association of Oncologists of Russia)
[25]
It is recommended to mark the tumor before starting
neoadjuvant therapy to enable visualization during
subsequent surgical treatment.
If it is impossible to perform SLNB or if a metastatic




Spain (Spanish Society of Medical Oncology)
[26]
ALND is recommended. In selected cN+ cases, in which
positive axillary node has been marked prior to NACT,
the identification and recovery of >2 negative SLNs
(including the marked node) with a double tracer
technique (Tc99 and methylene blue) may avoid ALND.
I, A
II, C
Table 3. Studies on sentinel node biopsy after neoadjuvant therapy in initially node-positive patients.
Study Number of Patients Preoperative AxillaryAssessment
Detection Rate of the
Sentinel Node False Negative Rate
SENTINA [4] 592 Clinical examination,ultrasound 80.1% 14.2%
SN FNAC [27] 153 Clinical examination,ultrasound 87.6% 8.4%
1










Meta-analysis [6] 3398 - 91% 13%
1 Sentinel nodes with isolated tumor cells [ypN0(i+)] defined as positive. 2 Only in patients with at least 2 sentinel nodes removed
(pre-defined study criterion); in case of only one sentinel node removed, the false negative rate was 29.3% [7].
In order to shed light on this much debated topic, the European Breast Cancer Research
Association of Surgical Trialists (EUBREAST) has initiated AXSANA (AXillary Surgery
After NeoAdjuvant Treatment), a multinational prospective cohort study (NCT04373655)
which enrolls cN+ patients undergoing NACT who convert to ycN0. The aim of AXSANA
is to assess the impact of different surgical staging procedures in the axilla on the oncologic
outcome and on health-related quality of life.
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2. Targeted Axillary Dissection: More Questions Open Than Answered
2.1. Which Marking Technique Is Optimal?
So far, several methods for marking of target lymph node(s) have been developed,
usually based on techniques that are already in use for the localization of non-palpable
breast lesions (Table 4). Interestingly, there are notable regional differences regarding the
use of various techniques. The same method may be the technique of choice in one country,
while being completely unknown in another.
Table 4. Possible options for marking and localizing suspicious lymph nodes prior to start of neoadjuvant chemotherapy
(modified after Reference [12]).







• Preoperative placement of a
radioactive/magnetic seed,
radar marker, or ink into the
clipped area (mostly
ultrasound-guided)
• Largest amount of data
• Reliable radiographic
visibility
• No radioactivity involved
• Relatively low cost
• Visibility on ultrasound varies widely
between studies, and a large part of the
axilla is not visible on a mammogram
• Preoperative localization necessary
(wire/seed) unless intraoperative
ultrasound is used
• Results from studies comparing different
clips not yet available
• Relatively low detection rate (rate of
successful target lymph node (TLN)
removal 70% in the largest available
dataset [28])
• Visibility of some clips (e.g., hydrogel
clips) may decrease over time
• Reaction of the node tissue to the clip
(especially hydrogel-containing clips)
may be misinterpreted on pathological
examination
• Some clips approved explicitly for
marking in the breast, not in the axilla
• Allergic reactions rare but possible
(some titanium clips contain nickel)
Radioactive seed Intraoperative localization usinggamma probe
• High detection rate
• No preoperative wire
localization necessary
• Transcutaneous localization
before skin incision possible
• Procedure not authorized in some
countries, requires complex radiation
safety procedures
• Signal reduction over time (i.e., in case of
longer chemotherapy due to
interruptions)
• High cost
• Allergic reactions rare but possible
(some seeds contain nickel)
Carbon suspension Intraoperative visualization
• No preoperative wire
localization necessary
• No radioactivity involved
• Low cost
• Limited data
• Marking cannot be localized without
surgical exploration of the axilla
• Possible ink migration
• Possible skin discoloration
• In case blue dye is used for SLNB, the
ink colors must differ
Magnetic seed Intraoperative localization usingmagnetic probe
• No preoperative wire
localization necessary
• No radioactivity involved
• Transcutaneous localization
before skin incision possible
• Very limited data
• Concerns regarding use in patients with
pacemakers and implantable
defibrillators
• Standard metal surgical tools should not
be used during measurement
• Allergic reactions rare but possible
despite very low nickel content
• MRI artifacts
• High cost
• Localization in deep tissue may result in
weaker signal (recommended depth max.
3.5 cm)
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Table 4. Cont.





• No preoperative wire
localization necessary
• No radioactivity involved
• Transcutaneous localization
before skin incision possible
• Very limited data
• High cost
• Allergic reactions rare but possible
(some markers contain nickel)
• Minimal MRI artifacts possible
• Interference with older halogen lights in
the operating theatre possible
• Adequate localization may be limited in







• No preoperative wire
localization necessary
• No radioactivity involved
• No decrease of signal over
time
• Transcutaneous localization
before skin incision possible
• Very limited data
• High cost
• MRI artifacts possible
• Concerns regarding use in patients with
pacemakers and implantable
defibrillators
To date, the largest amount of data has been published on clip-based targeted axil-
lary dissection (TAD). Unless intraoperative ultrasound is used, this strategy requires a
preoperative localization step, performed either by the use of a wire or by placing another
marker (e.g., magnetic or radioactive seed, radar marker or radiofrequency identification
[RFID] tag) into the clipped area that will allow identification during surgery. Still, the
success of target lymph node (TLN) removal depends on the ultrasound visibility of the
clip inserted before NACT.
The study that brought international attention to the technique was a retrospective
analysis of a prospective database at the M.D. Anderson Cancer Center (Table 5) [8]. Nearly
all patients in this study underwent ultrasound-guided placement of a radioactive iodine-
125 seed into the previously clipped node prior to surgery. This strategy offers more
flexibility than wire localization, which was used in two patients only, because the seed can
be inserted several days before surgery, whereas the wire placement is usually scheduled
for the morning before the operation or (rarely) the day before. The study by Caudle et al.
showed that the FNR of TAD can be as low as 2.0% [8]. However, since only patients with
successful preoperative localization were included in this analysis, it is unclear whether the
clip could not be visualized in some patients, making preoperative localization impossible.



















Ultrasound: 89% 78% TAD: 4.3%TLNB: 7.2%
Caudle 2016 [8] 208
Preoperative radioactive












[5,7] 203 None NR 83%
4
SLNB:
6.8% if TLN was
SLN
19% if TLN was not
SLN 5
Plecha 2015 [30] (in
98% HydroMARK
clip)
91 Wire localization in 74% ofpatients NR
97% in patients with


















Laws 2020 [31] 57
Preoperative placement of
a magnetic seed, a RRL clip
or a RFID tag into the
clipped area
98% 89% NR





Ultrasound: 72% 91% NR





Ultrasound: 100% 98% NR
ILINA trial [34]
(HydroMARK clip) 46 Intraoperative ultrasound Ultrasound: 96% NR TAD: 4.1%
3








Wire localization in 80% of
patients (67% US, 13%
mammography)
Ultrasound: 83%





Diego 2016 [37] 30
Preoperative radioactive















100% 100% SLNB alone: 21.4%TAD: 5.9%
Kim 2019 [39]
(UltraClip) 28









25 Wire localization NR 92% NR









0% if ≥2 marked
nodes were
removed




RISAS [43] 227 Gamma probe(intraoperative) NR 98% TAD: 3.5%
Donker 2015 [44] 100 Gamma probe(intraoperative)
100% (gamma
probe) 97% TLNB: 7%
3
Magnetic
seed Thill 2020 [45] 5
Magnetic probe





Sun 2020 [35] 7 Intraoperative radarlocalization 100% 100% NR
RFID tag Malter 2020 [46] 10 Radiofrequency probe(intraoperative) 100% 100% NR
Carbon
suspension




visualization 100% 100% NR
Allweis [49] 63 Intraoperativevisualization 95% 95% NR














Khallaf 2020 [50] 20 Intraoperativevisualization 95% 95%
TAD: 8.3%
SLNB alone: 15.3%
Gatek 2020 [51] 20 Intraoperativevisualization 100% 100% NR
Choy 2014 [52] 12 Intraoperativevisualization 100% 100% NR
1 Analyzed only in patients receiving ALND. 2 The clip was absent on postoperative axillary radiography in the remaining five patients,
suggesting clip dislodgement. 3 Lymph nodes with isolated tumor cells were considered positive. 4 In the remaining 17% of patients,
the clip was neither in the SLN nor in the ALND specimen. 5 Only in patients with ≥2 SLNs removed and initially cN1. Abbreviations:
ALND—axillary lymph node dissection, FNR—false-negative rate, MARI—marking the axillary lymph node with radioactive iodine
(125I) seeds, NACT—neoadjuvant chemotherapy, NR—not reported, RFID—radiofrequency identification device, RRL—radar reflector
localization, SLNB—sentinel lymph node biopsy, SLN—sentinel lymph node, TAD—targeted axillary dissection (removal of marked node
and SLN), TLN—target lymph node, TLNB—target lymph node biopsy, US—ultrasound.
The results of the prospective German multicenter SENTA register study were pre-
sented at the ESMO conference in 2019 and are now available as a full publication [28,29].
In this study, the TLN was clipped before NACT in 473 patients. A Tumark Vision clip
(SOMATEX®, Berlin, Germany) was used in the majority of cases (71%), followed by an
O-Twist clip (BIP, Türkenfeld, Germany) (12%). Clip types used in the remaining patients
have not been described. In 50 out of 473 patients, a targeted lymph node biopsy (TLNB)
was not attempted either because the clip was not visible upon preoperative ultrasound
or TLNB was for some reason not planned by the investigator. The TLN could be success-
fully removed in 329 of 423 patients, mostly after wire localization, resulting in an overall
removal rate of 78% among patients in whom a TLNB/TAD was attempted. The TLN
detection rates were higher in case a Tumark Vision or a O-Twist clip was used, compared to
other clips (79.7%, 78.4%, 69.4%, respectively). Interestingly, triple negativity and high Ki67
index were associated with TLNB failure (i.e., TLN not removed during TLNB attempt). In
63% of patients, the SLN and the TLN were identical. In the subgroup of 278 patients who
received ALND, TLNB alone and TAD resulted in FNRs of 7.2% and 4.3%, respectively.
Another marking method is the injection of a small volume (0.1–0.5 mL) of a carbon
solution into the suspicious lymph node. At surgery, the TLN is identified visually by its
dark staining. The results of TATTOO, the largest prospective trial on carbon solution-based
TAD, have been presented recently [47]. In 94% of 118 included patients, the marked node
could be detected intraoperatively. In 60% of cases, SLN and TLN were identical. In 5
(4.5%) patients, unintentional tattooing of the skin was observed, but it remains unclear
whether this effect is permanent. In 61 cN+ patients converting to ycN0, completion ALND
was performed. In this subgroup, three out of 33 patients with residual axillary disease
had not been correctly identified by TAD, resulting in a FNR of 9.1%. A similar FNR of
8.3% was reported from the only other study on FNR in carbon solution-based TAD [50].
The MARI technique (“Marking the Axillary lymph node with Radioactive Iodine
seeds”) was reported from the Netherlands in 2015 [44]. It implies that a titanium-
encapsuled radioactive seed is inserted into the suspicious lymph node before NACT under
ultrasound guidance. In contrast to technetium-99-based localization of non-palpable breast
lesions before primary surgery, the longer half-life (59 days) of iodine-125 allows for use
in the neoadjuvant setting. Donker et al. evaluated the MARI technique in 100 patients
scheduled for NACT [44]. Marking of the biopsy-proven positive lymph node and the
breast tumor using identical seeds was conducted at one procedure. In three patients, the
seed could not be properly positioned in the lymph node, resulting in a removal rate of
the biopsied node of 97%. No relevant loss of signal was observed after a median NACT
duration of 17 weeks, and all seeds could be removed successfully. Importantly, no SLNB
was performed in this study, and thus the reported FNR of 7% refers to the TLNB alone.
Two aspects have been critically discussed after the introduction of the MARI tech-
nique. First, the procedure requires complex safety regulations and cannot be performed
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in some countries due to national radiation protection laws. Secondly, both the local-
ization of iodine-125 and technetium-99 used for SLN mapping require a gamma probe
so interference might potentially occur in case of down-scatter of technetium-99m into
the energy spectrum of iodine-125. The first results of the RISAS trial (NCT02800317),
presented by Simons et al. at the San Antonio Breast Cancer Symposium in 2020 [53], could,
however, show that the combination of the MARI technique and SLNB is feasible: TAD
was successfully performed in 223 out of 227 (98%) patients. The trial was designed to test
the non-inferiority of TAD over ALND, with FNR as the main endpoint. Non-inferiority
was assumed if the upper bound of a 95% confidence interval around the FNR was lower
than 6.25%. Although the FNR was low (3.5%), the prespecified primary endpoint was
not met (95% confidence interval 1.38–7.16). The authors reported, however, that 4 out of
5 patients with a false-negative result (i.e., residual lymph node metastasis in the ALND
specimen despite tumor-free TAD) were found among the first 10 enrolled patients of
participating institutions, suggesting a learning curve that should be considered when
planning future studies.
Another technique to mark a biopsy-proven lymph node metastasis is based on the
placement of a magnetic seed. So far, the only magnetic seed for axillary node marking
evaluated in studies is the MagSeed® (Endomag, London, United Kingdom). The seed is
detected during surgery by using a magnetic probe called Sentimag® (Endomag, London,
United Kingdom) surgical guidance platform. This method has already provided evidence
for the successful resection of non-palpable breast lesions [54]. Its use for TAD was restricted
by the initial requirement to remove seeds within 30 days after placement, but recently,
both the Food and Drug Administration (FDA, 2018) and the Conformité Européenne (CE)
marking (2020) approved long-term implantation in any soft tissue, thus allowing use in
the neoadjuvant setting. First data on the magnetic seed-based TAD have been recently
published by Thill et al. [45]. This small study showed a detection rate of 100%. Since
magnetic seeds can lead to large magnetic resonance imaging (MRI) artifacts, it should be
used with caution in patients in whom MRI-based assessment of response during NACT
is planned.
Other possible techniques are radar reflector-localization clips [55] and radiofrequency
identification (RFID) tags [56,57], that have provided promising results for non-palpable
lesion localization, while data on lymph node marking are limited. Table 4 shows potential
advantages and disadvantages of various methods and Table 5 gives an overview of
current evidence.
2.2. How Many Nodes Should Be Marked?
Since TAD is a relatively new technique that still needs to be validated and standard-
ized, various institutions follow different strategies. So far, there is no consensus on the
number of nodes that should be marked in patients with more than one suspicious lymph
node on imaging. While most studies report the marking of a single node, it is unclear
which lymph node was selected for biopsy and marking in these cases. Options vary
between the largest, the “most suspicious”, or the best accessible lymph node [8,47]. Other
authors report marking of all suspicious nodes [42,48]. Both strategies offer their own
advantages and disadvantages (Table 6).
Regarding the accuracy of lymph node assessment, marking only one axillary lymph
node in case of patients with several suspicious or biopsy-proven nodes might increase
the FNR since the marked lymph node might be free of tumor while other previously
suspicious but not marked lymph nodes may still contain tumor residuals and remain in
situ. A heterogenous axillary response to NACT is common and can be diagnosed in up
to 74% of patients with hormone receptor-positive HER2-negative disease, followed by
29% in triple-negative and 25% in HER2-positive tumors [58]. Lim et al. conducted a small
study with a complex design to explore FNRs of different TLNB strategies in the same set
of patients [42]. All suspicious nodes of a patient were marked with different types of clips
to aid individual node identification (e.g., UltraCor Twirl, HydroMARK, and UltraClip).
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Altogether, 21 nodes in 14 patients were clipped. After NACT, all patients received TLNB
and ALND. The first clipped node alone had a FNR of 7.1%, which sank to 0% when the
second clipped node was taken into account. No SLNB was performed, and it remains
unclear how this might have influenced the FNR.
Table 6. Potential strategies regarding the number of marked nodes.
Only One Node Is Marked All Suspicious Nodes Are Marked
Advantages
• Lower cost
• Fewer nodes are removed at
surgery→ possibly less arm
morbidity
• Less challenging marking
procedure
• Lower FNR in small studies
→ possibly better oncological
outcome
Disadvantages
• Heterogenous response of
different nodes to therapy→
higher FNR→ possibly higher
recurrence rate
• High cost
• Higher probability that one of
the marked nodes will not be
removed successfully




Concerning arm morbidity, marking all suspicious nodes will necessarily result in
removal of more lymph nodes. Natsiopoulos et al. conducted carbon solution-based
TAD (Spot®, GI Supply, Inc., Mechanicsburg, PA, USA) in 75 patients [48], marking each
biopsy-proven or strongly suspicious node (median 2, range 1–5). At surgery, 2–10 nodes
(median 4) were retrieved. How this relatively high number of removed nodes may affect
quality of life and arm morbidity remains to be clarified. Importantly, a clinically relevant
balance between high accuracy (more extensive staging) and low morbidity (less extensive
staging) must be found.
2.3. When Should Lymph Nodes Be Marked?
To date, there is no consensus on the optimal timepoint of marker placement. In most
studies, lymph node metastases were confirmed by fine needle aspiration or core biopsy.
Such procedures, however, are not standard in some countries, and not all guidelines
recommend routine minimally invasive biopsy in case of suspicious findings. Especially in
case of large tumors and multiple highly suspicious nodes, clinicians may find it sufficient
to perform biopsy of the breast tumor only.
If a minimally invasive biopsy is performed, the marker may be inserted into the
same lymph node(s) at the same session or at a second session upon confirmation of
metastasis by pathology/cytology. Data on this aspect lack detail in available studies but
most authors report the placement of the marker into the “previously proven” node [44,48].
In contrast, marking of the suspicious lymph node immediately after the biopsy is reported
by others [31,52]. Table 7 provides an overview of advantages and disadvantages of
both strategies.
2.4. What to Do in Case of a “Lost Marker”?
A major concern expressed by clinicians trying to implement TAD at their institutions
is the uncertainty of how to deal with patients in whom the marker has not been retrieved at
surgery. Since a TAD/TLNB cannot be successfully performed in these patients, completion
ALND is an obvious choice. Still, in some patients, the marker will not be found in the
ALND specimen either. The pivotal study by Caudle et al. included 208 patients whose
metastatic nodes were clipped prior to NACT [8]. In five of these patients, the clip could
neither be identified in the surgical specimen nor upon radiography of the axilla, suggesting
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clip dislodgement. In another study, the clip could not be retrieved in two out of 73 patients,
but no further details were reported [30]. To date, the management of patients with lost
clips is unclear.
Table 7. Potential strategies regarding the time point of lymph node marking.
At Time of Biopsy After Pathological/CytologicalConfirmation of Nodal Metastasis
Advantages
• Only one invasive procedure
for the patient
• Certainty that the marking has
been placed into the biopsied
node
• The marker is placed only if
necessary, i.e., in case a
TLNB/TAD is planned
Disadvantages
• Some lymph nodes might be
marked unnecessarily→
higher cost
• In case of several suspicious
nodes, the marker may be
placed into the one that has
not been biopsied
• In case of reactive lymph
nodes due to biopsy, the
marker may be placed into a
benign node
• An additional invasive
procedure is necessary
In case of other markers, several additional concerns need to be addressed. Since
leaving radioactive seeds behind results in a major radiation regulation breech that must
be reported to regulation authorities, seed explantation should be attempted whenever
possible unless it would jeopardize patient’s well-being [59]. In case of magnetic seeds, no
radioactivity is involved, but leaving a magnetic marker in the axilla can result in large
MRI artifacts and thus compromise imaging assessment during post-treatment surveil-
lance. Minor MRI artifacts are also possible in case of unsuccessful radar marker or RFID
tag retrieval.
While lost clips can only be removed using imaging-guidance (usually radiography,
ultrasound, or computer tomography), radioactive and magnetic seeds as well as radar
markers and RFID tags can be identified using a special probe and carbon ink-marked nodes
can only be visualized intraoperatively during dissection of the axilla, possibly resulting in
different radicality of retrieval procedure and individual risk faced by the patient.
2.5. Is TAD Safe for All Patients?
It is yet unclear whether all cN+ patients can safely omit completion ALND in case
of negative axillary staging. So far, while none of the studies on TAD have reported
oncological outcome or health-related quality of life, there is limited information available
on SLNB alone in this setting. Kahler-Ribeiro-Fontana et al. have recently reported on
long-term outcomes following SLNB after NACT [3]. Among 222 clinically node-positive
patients, 123 had no residual axillary disease at surgery. Of these, only two patients (1.6%)
developed axillary recurrence after 3.6 and 5.5 years from surgery and were alive without
disease at the last follow-up. Among all cN1/2 patients, no significant differences in 5-year
and 10-year overall survival were found between patients who received ALND and those
in whom ALND was omitted.
Most TAD validation studies include heterogeneous groups of patients. In the pivotal
study by Caudle et al., nearly all patients had cT1–cT3 tumors, but 28% of patients presented
with at least four abnormal nodes on ultrasound [8]. Similarly, in the largest study on
carbon solution-based TAD, 25% of patients had ≥4 and 4% had ≥10 suspicious nodes
before NACT [47]. 124 out of 423 (29%) patients enrolled in the SENTA trial had at
least three abnormal nodes [29]. Intuitively, the more nodes appear suspicious on initial
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ultrasound, the more probable it is for the TAD to miss residual disease, especially in case
only one node was marked, thus resulting in a higher FNR [60].
Other factors that can improve identification of patients who do not benefit from com-
pletion ALND are breast response to therapy and tumor subtype. A multivariable analysis
of 13,396 patients showed that pathological complete response (pCR) n the breast was the
most important predictor of pCR in the axilla (odds ratio 20.37 for yT0) [61]. Other studies
reported a strong association between response in the breast and in the axilla, particularly
in patients with HER2-positive and triple-negative breast cancer [62–64], implying that
tumor subtype should probably also be implemented into a potential decision algorithm.
Since patients with HER2-positive and triple-negative cancer achieving radiological breast
response have the highest probability of reaching axillary pCR, they are probably most
likely to benefit from de-escalation of surgical treatment, such as TAD.
2.6. Beyond Surgical Therapy: Which Fields Should Be Irradiated after TAD?
Another controversial issue is the target volume for nodal irradiation. While some
guidelines exclude levels I and II from irradiation in case of a negative TAD, others
suggest to cover all regions if they have not been assessed with a therapeutic intent. More
specifically, it remains unclear whether patients with an extensive axillary tumor burden
who achieve pCR after NACT benefit from additional regional treatment.
Koolen et al. from the Netherlands Cancer Institute proposed a hypothetical algorithm
based on initial nodal status and response to NACT [65]. In this algorithm, patients receive
not only ultrasound but also PET-CT prior to NACT. Those with 1–3 positive nodes are
recommended no further axillary therapy in case of axillary pCR, defined as a negative
MARI procedure (i.e., resection of a radioactive seed-marked TLN) [44]. In case of non-pCR,
axillary radiotherapy is performed. For patients with ≥4 positive nodes before NACT,
axillary radiotherapy is always indicated but patients with non-pCR are also recommended
an ALND. In a cohort of 100 patients treated by TLNB (MARI) and ALND, the proposed
algorithm would have led to omission of ALND in 74%, and some patients potentially
risk under- (3%) or over-treatment (17%) [65]. Whether such tailored strategies might be
an acceptable compromise between high oncological safety on one side and lower arm
morbidity on the other remains to be clarified in future trials. In this context, the results
of the NSABP-B51 trial (NCT01872975) are expected to be published in 2023. This phase
III clinical trial is designed to test whether regional nodal irradiation (RNI) improves the
recurrence-free interval rate in women with cN1 breast cancer before NACT who become
pathologically node-negative at the time of surgery. Patients who undergo mastectomy
are randomly assigned to observation or radiotherapy to the chest wall and undissected
axilla, internal mammary nodes, and ipsilateral supraclavicular fossa, whereas women who
undergo breast-conserving surgery are randomized to adjuvant whole breast irradiation vs.
whole breast and regional nodal irradiation. In the ALLIANCE A011202 (NCT01901094)
trial, women with node-positive status before NACT receive SLNB at the time of surgery.
Patients with axillary residual disease are randomized to completion ALND and RNI vs.
RNI alone.
3. The AXSANA Study: Which Axillary Strategy Is Optimal in the cN+→
ycN0 Setting?
AXSANA, initiated by EUBREAST (http://axsana.eubreast.com; accessed on 27
March 2021, Figure 1), is a large, prospective, non-interventional cohort study aiming
to evaluate the role of axillary treatment in cN+ patients undergoing NACT. With a target
accrual of 3000 patients, the study is expected to be able to resolve several open issues.
Patients with clinically positive nodal status at time of diagnosis who are scheduled to
receive axillary surgery after NACT can be enrolled. Axillary staging procedures and
treatment modalities are chosen at the discretion of the treating physicians and according
to national and institutional guidelines. Inclusion and exclusion criteria are presented in
Table 8. Follow-up is annually during the first five years after surgery. Arm morbidity
and quality of life are evaluated at baseline and after 1, 3, and 5 years, using four val-
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idated questionnaires (EORTC QLQ-C 30, EORTC QLQ BR 23, Lymph-ICF, and Sense
of Coherence). Financial support has been provided by the AGO-B study group, the
AWOgyn (German Working Group for Reconstructive Surgery in Oncology-Gynecology),
Claudia von Schilling Foundation for Breast Cancer Research, EndoMag, Mammotome,
and MeritMedical. AXSANA is further supported by the North-Eastern German Society of
Gynecological Oncology (NOGGO) and the German Breast Group (GBG).
Table 8. The AXSANA study: Inclusion and exclusion criteria.
Inclusion Criteria Exclusion Criteria
• Signed informed consent form
• Primary invasive breast cancer
(confirmed by core biopsy)
• cN+ (confirmed by core biopsy/fine
needle aspiration or presence of highly
suspicious axillary node(s) on imaging)
• In case a minimally invasive biopsy of
axillary lymph node(s) has been
performed and yielded a negative or
inconclusive result, patients may be
included if the final classification after
imaging-pathology-correlation is cN+
• cT1–cT4c
• Scheduled for neoadjuvant systemic
therapy






History of invasive breast cancer, ductal
carcinoma in situ, or any other invasive cancer
Confirmed or suspected supraclavicular lymph
node metastasis
Confirmed or suspected parasternal lymph
node metastasis
Axillary surgery before NACT (e.g., SLNB or
nodal sampling)
Pregnancy
Less than 4 cycles of NACT administered
Patients not suitable for surgical treatment
Primary study endpoints:
• 5-year invasive disease-free survival (iDFS)
• 3-year axillary recurrence rate
• Quality of life and arm morbidity
Secondary study endpoints:
• Feasibility of different axillary staging strategies assessed by detection rates for SLN
and/or TLN
• Success rate of nodal staging using different axillary staging techniques
• Number of removed lymph nodes and their association to complications, arm morbid-
ity, and quality of life
• Operating time as a surrogate parameter for surgical resources
• Proportion of node-positive patients according to the strategy used (as a surrogate
parameter for FNR)
• Factors associated with successful detection of the TLN
• Impact of learning curve on success rates of TAD
• Surgical standards of care in different European countries
• Treatment decisions in case of ypN+ status following NACT (ALND vs. radiation therapy)
• iDFS in patients with ypN+ status who received ALND or radiotherapy or both
• Analysis of factors contributing to a decreased quality of life and subjective symptoms
of arm morbidity, i.e., baseline quality of life and sense of coherence, extent of axillary
surgery, and other locoregional and systemic therapies received
• Economic resources required for different axillary staging strategies and techniques
(material costs, operating time, etc.)









Figure 1. AXSANA flow chart.
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The first AXSANA study site was opened in Germany in June 2020, and recruitment
began the same month. Currently, there are 328 patients enrolled. Twenty countries are
participating in the study, most of which are in the process of applying for ethical approval.
Ten countries have at least one study site open (Figure 2). The study will hopefully address
several unanswered issues, such as:
• Which staging technique should be recommended to cN+ patients converting to ycN0?
• Is imaging helpful in identifying patients most likely to achieve pCR in the axilla? If
yes, which method should be recommended?
• Should cN1 and cN2/3 patients be offered different surgical strategies for axillary staging?




Figure 2. Current status of the AXSANA study.
Due to high complexity and discordant recommendations, a randomized trial compar-
ing different techniques seems hardly feasible and therefore would not clarify currently
open issues within a reasonable timeframe. In the AXSANA study, patients are treated
at physicians’ discretion. To allow comparisons between different cohorts (SLNB, TLNB,
TAD, ALND), detailed data regarding clinical and pathological parameters are obtained.
Other currently ongoing studies investigating axillary management in the neoadjuvant
setting in cN+ patients are presented in Table 9.
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Table 9. Current trials investigating de-escalation of surgical treatment in cN+ patients undergoing neoadjuvant therapy.
Study Status Study Design Primary Endpoint(s)




Marking technique: clip or carbon
suspension
Arms: axillary treatment (ALND
or ART) vs. no axillary treatment
DFS
Patient-reported lymphedema
AXSANA NCT04373655 Recruiting since June 2020 Non-interventional cohort studycN+ patients
iDFS
Axillary recurrence rate
Quality of life and arm morbidity
GANEA 3 NCT03630913 Recruiting since January 2019
Single-arm trial
cN+ patients (confirmed by
biopsy)
Surgery: TAD followed by ALND
Marking technique: clip, marking
of the most suspicious node only





cN+ patients (confirmed by
biopsy)
Surgery: TAD
Marking technique: clip and
magnetic seed
Retrieval rate of clipped node and
magnetic seed
Pre-ATNEC NCT03640819 Completed, results pending
Single-arm trial
cN+ patients (confirmed by
biopsy)




Identification rate of marked
lymph node(s)
RISAS NCT02800317 Completed, full publicationpending [43,53]
Single-arm trial
cN+ patients (confirmed by
biopsy)
Surgery: TAD followed by ALND
Marking technique: Radioactive
iodine seed
Identification rate, accuracy, and
false negative rate
TATTOO DRKS00013169 Completed, full results pending[47,66]
Single-arm trial
cN+ patients (confirmed by
biopsy)
Surgery: TAD or TLNB + ALND
Marking technique: carbon
suspension
Detection rate of the TLN
TAXIS [67]
NCT03513614 Recruiting
Randomized phase III trial
cN+ patients
Surgery: tailored axillary surgery
with or without ALND followed
by radiotherapy
DFS
NCT03718455 Terminated due to limitedoperating room availability
Single-arm trial











Rate of successful removal of the
TLN
Abbreviations: ALND—axillary lymph node dissection, ART—axillary radiation therapy, DFS—disease-free survival, iDFS—invasive
disease-free survival, TAD—targeted axillary dissection, TLN—target lymph node.
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4. Conclusions
In view of continuously improving primary systemic treatments with increasing
response rates, there is an urgent need to adapt and de-escalate strategies for axillary
surgery, since it is strongly associated with postoperative morbidity. While SLNB has
successfully replaced ALND as a staging procedure in primary surgery and after NACT
for patients with an initial cN0 status, there is an ongoing debate on appropriate axillary
staging for patients who convert from cN+ to ycN0.
This review revealed heterogeneous guideline recommendations and practice through-
out the international community. This observation is explained by the lack of evidence
concerning minimally invasive staging procedures like SLNB or TAD and their association
with oncological outcomes, arm morbidity, and quality of life. The review also identified
a multitude of unresolved issues regarding indications, surgical staging procedures, and
technical aspects of lymph node marking. As a consequence, the European Breast Can-
cer Research Association of Surgical Trialists (EUBREAST) initiated a prospective cohort
study that will allow the assessment of clinically relevant parameters in different axillary
staging procedures after NACT, and of many open issues that have been highlighted here.
AXSANA is open for all countries provided that patients receive treatment according to
current international standards (http://axsana.eubreast.com, accessed on 27 March 2021).
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Appendix A.1. Members of the AXSANA Study Group
Achim Rody Lelia Bauer
Agnieszka Lawnicka Manfred Hofmann
Alexander Emelyanov Manuela Seixas
Alexander Miller Maria Hufnagel
Anastasia Fleuster Maria Joao Cardoso
Andrea Hasse Marina Mangold
Andrea Papadia Marjut Leidenius
Andrea Stefek Markus Hahn
Andreas Rempen Markus Keller
Andreas Schnelzer Martin C. Koch
Andree Faridi Matthias Frank
Angelika Jursik Michael Berghorn
Anja Graf Michael Burkhardt
Anke Klein-Tebbe Michael David Mueller
Antje Nixdorf Michael Schrauder
Antonio Jesus Esgueva Colmenarejo Michael Untch
Arzu Akan Michael Weigel
Atakan Sezer Michal Bak
Aysegul Aktas Muneer Mansour
Barbara Schlesinger Mustafa Aydogdu
Beatrix Janke Mustafa Celalettin Ugur
Benno Lex Nana Bündgen
Carina Paschold Natalia Krawczyk
Carolin Nestle-Krämling Natalija Deuerling
Cem Yilmaz Nicole Rotmensz
Christine Ankel Nicoleta Zenovia Antone
Christoph Anthuber Nina Ditsch
Christoph Großmann Ninette Scharle
Cihan Uras Oliver Behrens
Claudia Rauh Oliver Hoffmann
Cordula Müller Oumar Camara
Cornelia Meisel Pavlina Diem
Cumhur Arici Petra Bolkenius
Daniela Dieterle Prodromos Kanavidis
Daniele Bolla Renu Buss-Steidle
Dirk G. Kieback Ricardo Felberbaum
Dirk-Michael Watermann Richard Berger
Dorothea Fischer Roberto Rodriguez
Eike Simon Rodoniki Iosifidou
Ekkehard von Abel Roland Csorba
Elisabeth Thiemann Sabine Lemster
Elke Faust Sabine Riemer
Elke Keil Sandra Rauen
Elvira Schomann Sarah Fröhlich
Emmanuel Barranger Sebastian Wojcinski
Enes Arikan Semra Gunay
Eva-Maria Jahn Sibel Ozkan Gurdal
Felix Hilpert Sibylle Perez
Florian Ebner Silke Mattes
Francesco Meani Sonja Cárdenas-Ovalle
Frank Beldermann Stefan Hupfer
Gabriele Feisel-Schwickardi Stefan Paepke
Gabriele Kaltenecker Stefan Renner
Gunay Gurleyik Stefanie Buchen
Hanna Barmettler Stefanie Strobel
Hanna Karlsson Steffen Liebers
Hans-Christian Kolberg Stephan Hasmüller
Hans-Joachim Strittmatter Stephan Seitz
Hasan Karanlik Sudip Kundu
Heiko Graf Susanne Albrecht
Helena Ikonomidis Sackey Susanne Bucher
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Henning Eichler Susanne Kraudelt
Inga Bekes Susanne Steer
Ingo Bauerfeind Susen Schirrmeister
Ingo Thalmann Sven-Thomas Graßhoff
Ingrid Buck Tanja Fehm
Ioannis Natsiopoulos Tanja Wanik
Isabelle Himsl Telja Pursche
Isabelle Utz-Billing Thomas Hawighorst
Jana Shabbir Thomas Müller
Jeanette Zeppenfeld Thomas Papathemilis
Jenci Palatty Tuomo Meretoja
Jens Paul Seldte Umit Ugurlu
Jens Schnabel Ursula Makowiec
Joachim Rom Ursula Scholz
Jose Ignacio Sanchez Mendez Ute-Susann Albert
Jürgen Schuster Vasileios Sevas
Jutta Lefarth Veli Vural
Karen Wimmer Visnja Fink
Kathrin Engelken Vlad Alexandru Gata
Katja Vassilev Volker Hanf
Katrin Sawitzki Wencke Ruhwedel
Kerstin Hilmer Wolfram Seifert
Kerstin Ramaker Yvonne Wengström
Kilian Pankert
Appendix A.2. Active Study Sites
Austria





Städtisches Klinikum Karlsruhe Frauenklinik
Klinikum Aschaffenburg-Alzenau
Klinikum Stuttgart-Frauenklinik








Brustzentrum, Sana Klinikum Berlin Lichtenberg
RWTH Uniklinik Aachen
Medius Klinik Nürtingen







Vidia Christliche Kliniken Karlsruhe Diakonissenkrankenhaus
Agaplesion Krankenhaus Frankfurt
Klinikum Gütersloh
Siloah St Trudpert Klinikum
Brustzentrum Donau-Riß, Alb-Donau-Klinikum Ehingen
Franziskus Hospital Bielefeld
Brustzentrum Gelnhausen









Agaplesion Ev. Klinikum Schaumburg























Klinikum Dritter Orden, München
Euregio Brustzentrum Eschweiler
DRK Krankenhaus Chemnitz Rabenstein
Diako Flensburg
Klinikum Ernst von Bergmann










Brustzentrum Elisabeth Krankenhaus Kassel
Greece
Laiko Hospital, National and Kapodistrian University of Athens, Athens










“Prof. Dr. Ion Chiricuta” Institute of Oncology
Spain
Clinica Universidad de Navarra, Madrid
Hospital Clinic Barcelona
Hospital Universitario La Paz-Unidad de Mama
Switzerland
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Turkey
Zonguldak Bulent Ecevit University, The School of Medicine
Trakya University Te School of Medicine
Ministry of Health Istanbul Provincial Health Directorate Prof. Dr. Cemil Taşcioğlu City Hospital
Marmara University, The School of Medicine
Ministry of Health Istanbul Provincial Health Directorate Istanbul Haydarpasa Numune Research and
Training Hospital
Akdeniz University, The School of Medicine
Namik Kemal University, The School of Medicine
Istanbul University Oncology Institute
Istanbul Oncology Hospital
Acibadem University Research Institute of Senology
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